• In early July 2026, GE HealthCare and Mayo Clinic announced the MI-BET research collaboration, using GE HealthCare’s StarGuide SPECT/CT and biomarker data to explore more personalized radioligand therapy for advanced prostate cancer patients at Mayo’s Rochester campus.
• A distinctive aspect of MI-BET is its use of imaging and blood-based biomarkers to potentially inform adaptive treatment pauses, supporting more tailored, data-driven theranostics and strengthening GE HealthCare’s role in precision oncology tools.
• We’ll now explore how this push into biomarker-guided theranostics and real-world evidence generation could reshape GE HealthCare’s existing investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

GE HealthCare Technologies Investment Narrative Recap

To own GE HealthCare, you need to believe it can turn its broad imaging and diagnostics footprint into steadier, higher quality earnings, despite tariff pressure, China uncertainty and rising competition. The MI-BET collaboration with Mayo Clinic highlights its push into precision oncology tools, but does not appear to change the near term focus on margin recovery and cash flow, where tariffs and input costs remain a key risk.

Among recent developments, the Allia platform upgrade pathways are especially relevant. Like MI-BET, they lean on software, AI and workflow tools to deepen ties with existing customers and expand recurring, higher margin revenue streams. For investors watching product pipeline catalysts such as radiopharmaceuticals and Photon Counting CT, Allia’s retrofit model shows how GE HealthCare may seek to unlock more value from its installed base while newer modalities, including theranostics, mature.

But while MI-BET is exciting, investors should also be aware of how persistent cost inflation could...

GE HealthCare Technologies’ narrative projects $24.0 billion revenue and $2.6 billion earnings by 2029. This requires 4.5% yearly revenue growth and a roughly $0.7 billion earnings increase from $1.9 billion today.

Uncover how GE HealthCare Technologies' forecasts yield a $79.72 fair value, a 23% upside to its current price.

Exploring Other Perspectives

These Mayo theranostics moves sit beside a much more optimistic analyst narrative, where the bullish camp was penciling in about US$24.8 billion of revenue and US$2.8 billion of earnings by 2029, so it is worth asking whether biomarker guided oncology and radiopharmaceutical uptake really support that faster growth path or if margin pressures could keep outcomes closer to the consensus view.

Explore 3 other fair value estimates on GE HealthCare Technologies - why the stock might be worth as much as 75% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your GE HealthCare Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free GE HealthCare Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GE HealthCare Technologies' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.